title: [Rehabilitation of patients with urolithiasis after minimally invasive procedures on the kidneys].
abstract: Minimally invasive surgeries in patients with urolithiasis are not always successful. Prevention of inflammatory and cicatrical-sclerotic complications in the postoperative period plays an important role. 49 patients with urolithiasis divided into two groups were followed-up. The study group included 25 patients who underwent percutaneous puncture nephrolitholapaxy. The control group consisted of 24 patients with a history of percutaneous puncture nephrolitholapaxy. In postoperative period, active prevention of inflammation and cicatrical-sclerotic complications using drug Longidaza in combination with magnetic-laser therapy was performed in study group. The control group received standard treatment. 6 months after surgery, 1 (4%) patient in the study group had pyeloectasis approximately 2 cm and obstruction of UPJ of operated kidney, which required re-treatment with Longidaza. In the control group, pyeloectasis and violation of passage through the upper urinary tract were recorded in 4 (16.7%) patients. These data allow to recommend a comprehensive prevention of postoperative inflammation and cicatrical-sclerotic complications using Longidaza and magnetic-laser therapy in patients undergoing minimally invasive surgery of the kidney.
authors.forename: V P
authors.initials: VP
authors.lastname: Avdoshin
authors.forename: M I
authors.initials: MI
authors.lastname: Andriukhin
authors.forename: T A
authors.initials: TA
authors.lastname: Kiriukhina
authors.forename: I V
authors.initials: IV
authors.lastname: Zaĭtseva
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000627:therapeutic use*; D008096:Lithotripsy / Q000009:adverse effects* / Q000379:methods; D028022:Low-Level Light Therapy / Q000379:methods*; D055909:Magnetic Field Therapy / Q000379:methods*; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000379:methods; D009403:Nephrostomy, Percutaneous / Q000009:adverse effects* / Q000379:methods; D011183:Postoperative Complications / Q000517:prevention & control; D016896:Treatment Outcome; D052878:Urolithiasis / Q000534:rehabilitation* / Q000601:surgery
chemical_list: D006821:Hyaluronoglucosaminidase